Enclomiphene Citrate Missed-Dose Protocol

Why no missed-dose rule exists

Missed-dose instructions come from a product label, and enclomiphene has no approved label. FDA's June 2022 advisory-committee materials state that no FDA-approved drug contains enclomiphene as its active ingredient [1]. EMA's committee recommended refusing marketing authorisation for EnCyzix (enclomifene) in January 2018 [5]. Compounded enclomiphene has not been reviewed by FDA for safety, effectiveness or quality [6]. Any catch-up advice is inference from the drug's pharmacokinetics, not a regulator's instruction.

What the time course does and does not tell you

Oral enclomiphene is absorbed quickly, with peak levels 2 to 3 hours after a dose and a half-life of about 10 hours; its main metabolite is 4-hydroxy enclomiphene and excretion is mainly in feces [1]. A half-life of about 10 hours does not by itself establish how a late or extra dose changes drug exposure or hormone levels.

The trials measured hormones after weeks of daily dosing, not around individual pills. By 12 weeks in ZA-301, 78.8% of men on enclomiphene (95% CI 70.3 to 85.3, n=113) reached an average 24-hour testosterone in the 300 to 1040 ng/dL range; in ZA-302 the figure was 81.3% (95% CI 73.9 to 87.0, n=134) [3][4].

What about doubling a dose

The clomiphene citrate label covers the two-isomer mixture, not enclomiphene alone. Its overdose section lists nausea, vomiting, vasomotor flushes, visual blurring, spots or flashes, and scotomata when more than the recommended dose is taken [7]. Its warnings report visual symptoms including blurring, spots, flashes and scotomata, and note that some visual disturbances may persist; those warnings apply to the clomiphene mixture and are not proven for enclomiphene alone [7].

Eye effects concerned regulators reviewing enclomiphene too: FDA listed cataracts seen in nonclinical studies, and EMA wanted ocular monitoring [1].

Missing days versus stopping

The closest published observation comes from a phase 2 study of 12 men previously on topical testosterone: after enclomiphene was stopped altogether, total testosterone fell back to pre-treatment values by one month [8]. That describes stopping, not one missed pill.

Safety concerns regulators flagged

FDA's 2022 review listed cardiac and thromboembolic events, including pulmonary embolism and deep vein thrombosis in a safety study, along with raised estradiol, raised PSA and raised hematocrit, and noted there are no long-term safety data [1]. EMA recorded a slightly higher rate of cardiac and thromboembolic events than with testosterone [1]. In the phase 3 and EMA data the most frequent side effects were headache, hot flushes, nausea and muscle spasm; in ZA-302 headache was reported by 7 of 112 men on 12.5 mg versus 1 of 47 on placebo [4].